NMDA receptor regulation of memory and behavior in humans
John W. Newcomer, John H. Krystal
Hippocampus October 1, 2001 DOI: 10.1002/hipo.1069 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | NMDA receptor antagonist drugs |
| Keywords | Nmda receptor Memory consolidation Glutamate receptor Hippocampus |
| Citations | 238 |
| Key findings | NMDA receptor hypofunction impairs memory encoding and consolidation, can produce psychosis-like symptoms and dissociation, and sustained underactivation leads to neurotoxicity. |
Abstract
N-methyl-D-aspartate (NMDA) receptor hypofunction is associated with a range of effects on cognition and behavior in whole animal and human studies. NMDA receptor hypofunction within the brain, which can be induced experimentally in vivo using NMDA receptor antagonist drugs, produces adverse effects on memory function. The results suggest that NMDA receptor hypofunction can preferentially affect neural mechanisms regulating the efficiency of encoding and consolidation into longer-term storage. More pronounced NMDA receptor hypofunction can produce a clinical syndrome that includes core features of psychosis, as well as dissociation. Finally, sustained and severe underexcitation of NMDA receptors in the adult brain is associated with a neurotoxic process with well-characterized neuropathological features. Progressive increases in severity of NMDA receptor hypofunction within the brain can produce a range of effects on brain function, involving local and distributed circuitry, which may underlie the observed changes in behavior. As the brain ages, the NMDA receptor system becomes progressively hypofunctional, potentially contributing to further age-related decreases in memory and learning performance. Pharmacological and genomic methods for preventing NMDA receptor hypofunction, or for preventing the upstream or downstream consequences modeled by treatment with NMDA antagonists, may be applicable to the prevention and treatment of memory and behavioral dysfunction in a variety of neuropsychiatric disease conditions.
Citations in the library
Cited by 8
- Effects of Different Subanesthetic Doses of (S)-Ketamine on Neuropsychology, Psychopathology, and State of Consciousness in Man Neuropsychobiology 2005
- mGlu2/3 Receptor Antagonists as Novel Antidepressants. TIPS - Trends in Pharmacological Sciences June 2017
- GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. Behavioural Brain Research February 15, 2016
- MK-801 Impairs Cognitive Coordination on a Rotating Arena (Carousel) and Contextual Specificity of Hippocampal Immediate-Early Gene Expression in a Rat Model of Psychosis Frontiers in Behavioral Neuroscience March 12, 2014
- Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task. Neuroimage June 29, 2011
and 3 more in the library
Cites 18
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- Study of a New Schizophrenomimetic Drug—Sernyl Archives of Neurology And Psychiatry March 1, 1959
- NMDA Antagonist Neurotoxicity: Mechanism and Prevention Science December 6, 1991
and 13 more in the library